comprehensive -WSS

comprehensive

author：explore 2025-10-01 00:59:29 - browse：533

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Protect nursing home residents from future pandemics

leisure time

WSS

An Ebola outbreak presents a new mystery involving children

Ohioans vote in high

Achieving telehealth equity for people with hearing loss

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Congress: Prevent baby formula shortages by passing a new bill

explore

comprehensive

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sage's campaign to raise awareness of postpartum depression hits a nerve

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Guardant Health colon cancer test endorsed by FDA advisory panel

Anesthesiologist group: stop taking Ozempic before surgery

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Virginia high school admissions case could be legal follow

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

Psychedelics group wrestles with new pharma identity

Decentralized clinical trials need collaboration to achieve wider use

focus

Hospitals need to get ahead of regulations on climate change

hotspot

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Germany receives 178 compensation applications from gay servicepeople over discrimination

Ohioans vote in high

Protect nursing home residents from future pandemics

knowledge

focus

leisure time

focus